Searched for
SAUMEN CHAKRABORTY
Expect to launch 25 products in US this fiscal: Dr Reddy'sDr Reddy's Laboratories expects to launch 25 products in the US market in the current financial year, according to a top company official. ...- DRL jumps 4% as firm looks to increase R&D expenditureThe pharma major reported a 44 per cent year-on-year (YoY) rise in profit at Rs 434.40 crore.
- Dr Reddy's to spend upto $ 300 million on R&D in FY 20The R&D spend for the quarter (January-March FY 19) is Rs 366 crore, that is USD 53 million and EBIT 9.19 per cent of the sales for the qua...
- Suboxone verdict will be the most important trigger for US market: Saumen Chakraborty, Dr Reddy’sSituation improving in parts of EM including Brazil and other LatAm countries, says the DRL president.
- US still most important market, EMs come next: Saumen Chakraborty, Dr Reddy's“No much opportunity for margins in plain vanilla generics.”
- Dr Reddy's climbs 3% as API plant receives no USFDA observationThe company is expecting to launch over 15 products in the US market in 2018-19.
- Price erosion in US impacted Q1 margins: Saumen Chakraborty , Dr Reddy's LabsIf competitions are higher, then definitely it leads to more price erosion but we will have to definitely work on those molecules where com...
- Don't believe worst is over in terms of financials: Saumen Chakraborty, Dr Reddy'sIn an exclusive chat with ET Now, Saumen Chakraborty, CFO, Dr Reddy's, said that some of the drugs that were to be launched in Q4 has now b...
- Budget 2016: Pharma sector was continue to be incentivised for boost in exports, says Dr Reddy's Saumen Chakraborty"If I talk to my peers from the health care industry from the corporate hospitals, they do not find investment is attractive in small towns"
- Sunset clause for SEZs 'at odds' with Make in India: Dr Reddy'sDr Reddy's Laboratories has said the Centre's decision to introduce sunset clause for Special Economic Zones from March 2017 is "at odds" w...
- USFDA observations relate to quality control testing: Saumen Chakraborty, Dr Reddy's"There are some API sales which have been happening. We are just getting all the numbers right."
- Dr Reddy's cracks 11% on USFDA warning for API facilitiesReacting to the report, the scrip slumped 11.6 per cent to hit a low of Rs 3,758.95. The company's generates 10-12 per cent of its revenue ...
- Dr Reddy’s Laboratories eyes in-licensing pacts with European, Japanese firms to spur domestic revenueChief Financial Officer Saumen Chakraborty confirmed the ongoing talks with global firms for in-licensing agreements, but refused to divulg...
- Greece crisis not to hurt software exports: Export bodyThe default crisis of Greece will have marginal impact on software exports, an export promotion council official said today.
- Weak US sales growth hits Dr Reddy's net profitThe global generics business, which contributes 82 per cent of total revenues, grew 8 per cent at Rs 3,169 crore.
- Dr Reddy's Laboratories may spend Rs 1,000 cr on capex next fiscalDRL is set to invest more than Rs 1,000 crore on capital expenditure in the next financial year, a top executive of the pharma major said h...
- Dr Reddy's Q3 Net zooms 70% to Rs 618 crore on drug sales in USDr Reddy's Laboratories Ltd today reported an over 70 per cent jump in net profit at Rs 618.42 crore for the third quarter ended December 3...
- Dr Reddy's Laboratories posts 76% jump in Q2 net profit at Rs 690 croreGeneric revenues from North America was up 43 per cent at Rs 1,324 crore during the quarter, as against Rs 927 crore in the year-ago period.
- Getting emotional about a bad appraisal is a natural reactionGetting emotional about a bad appraisal is a natural reaction from employees, but it does not help in any way,” says Saumen Chakraborty of ...
- DRL bets on India plan for German armDr Reddy’s Laboratories (DRL) aims to shift production of about a dozen top-selling products of its German arm Betapharm to India by July 2...
Load More
